2030 年人类微生物组市场预测:按产品、疾病、类型、应用和地区进行的全球分析
市场调查报告书
商品编码
1383331

2030 年人类微生物组市场预测:按产品、疾病、类型、应用和地区进行的全球分析

Human Microbiome Market Forecasts to 2030 - Global Analysis By Product (Medical Foods, Prebiotics, Probiotics, Symboitics and Other Products), Disease, Type, Application and By Geography

出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据,2023 年全球人类微生物组市场规模将达到 8 亿美元,预计到 2030 年将达到 63 亿美元,预测期内年复合成长率为 34.1%。

「人类微生物组市场」一词定义了专注于人类微生物组的彻底研究、分析和商业性应用的生物技术和医疗领域。它由研究、诊断、治疗和个人化医疗等各个领域组成,旨在了解人体与其栖息的微生物之间的共生相互作用。

根据美国癌症协会估计,2022 年美国将报告约 1,918,030 例新癌症病例。此外,根据Globocan 2020统计,新增癌症病例数为274,364例,预计2040年将达到400,564例。

微生物组研究进展

过去几十年来,微生物组研究取得了重大进展,使我们对微生物组与人类健康和疾病的关係的理解发生了重大变化。此外,由于高通量序列测定方法和强大的生物资讯工具,现在可以对人体内存在的大量微生物群落进行彻底分析和表征。

法规墙

主要问题之一是微生物产品和治疗方法缺乏透明和统一的法规流程。基于微生物的产品和治疗方法缺乏简单而统一的法律规范可能会限制市场扩张并增加进入障碍。然而,微生物群落的多样性和人类微生物组的动态性质在评估产品安全性和功效时给法规机构带来了挑战。

慢性病盛行率呈上升趋势

肥胖、糖尿病、发炎性肠道疾病疾病和自体免疫疾病等慢性疾病在世界各地变得越来越普遍。因此,医学相关人员和学者正在探索以微生物为基础的疗法,以便更好地了解和管理这些慢性疾病。此外,许多发育技术都涉及恢復慢性病患者的微生物平衡,包括益生菌、粪便微生物移植 (FMT) 和微生物组控制。

研究开发费用

微生物组研究领域需要在研发 (R&D) 方面进行大量投资,以充分了解人类微生物组的复杂性并开发基于此的产品和排除项。益生菌和益生元等微生物治疗方法的开发、资料分析、临床试验和微生物组定序都包含在这些支出中。然而,可用产品和治疗方法的多样性受到高昂的研发成本的阻碍,这可能会阻止小型企业和新兴企业进入市场。

COVID-19 的影响:

全球范围内的临床试验研究因 COVID-19 大流行而受到严重干扰。鑑于研究通常包括贫困阶级,他们最容易接触到 COVID-19,这一点尤其重要。同样,COVID-19 已经并可能对其他公司的营运产生负面影响,包括微生物药物和诊断设备的临床前研究和临床试验。

预计益生菌产业在预测期内将是最大的

预计益生菌产业在预测期内将达到最高水准。益生菌是活的微生物,当以足够的比例给药宿主时,可以透过恢復或维持肠道菌丛来改善或维持宿主的整体健康。由于它能够促进免疫健康、帮助消化和影响一般健康的许多组成部分,因此它变得非常受欢迎。此外,随着人们越来越重视预防性健康和保健,随着客户寻求针对医疗问题的微生物友善治疗方法,益生菌产业预计将会成长。

预计诊断领域在预测期内将呈现最高的年复合成长率。

随着人们越来越认识到人类微生物组在健康和疾病中发挥的重要作用,诊断领域预计将在预测期内呈现最高成长率。由于定序技术和生物资讯学的进步,微生物组诊断可以更深入地了解人体微生物种群,从而实现个体化和精确的治疗。此外,微生物组诊断由于其在支持疾病早期检测、指导个体化治疗策略和评估干预措施成功与否方面的潜力而在医疗保健领域变得越来越普及。

比最大的地区

北美地区占最大份额,原因在于其完善的医疗设施网络、大公司加大对开发更先进技术的投资以及加速新药开发进程。这一领域正变得更加活跃。此外,人类微生物组治疗正在引起人们的关注,与文明病变得越来越普遍,人类微生物组的次世代定序和技术进步正在取得进展。所有这些因素都促进了该地区的市场成长。

复合年复合成长率最高的地区:

由于消费者对益生菌、益生元和微生物组相关产品的兴趣不断增加,预计亚太地区将实现盈利增长。这是因为微生物组在消化、营养健康和整体健康方面的重要性正在广泛认可。此外,亚太地区微生物组科学领域的研发活动正在增加,特别是在中国、日本和韩国等大力投资生物技术和生命科学的国家。

2022年5月,一家开发针对癌症、气喘、自闭症和关节炎等自体免疫疾病等疾病的生物治疗产品的全球製药公司4D Pharma宣布,4D Pharma是一家针对癌症等疾病开发生物治疗产品的全球製药公司、气喘、自闭症和关节炎等自体免疫疾病宣布,针对癌症、气喘、自闭症和关节炎等自体自体免疫疾病等疾病开发生物治疗产品的全球製药公司4D Pharma宣布宣布开展MRx0518的临床试验与 PD-L1 阻断抗体 Babencio 合併使用。

免费客製化服务:

订阅此报告的客户可以存取以下免费自订选项之一:

  • 公司简介
    • 其他市场参与企业的综合分析(最多 3 家公司)
    • 主要企业SWOT分析(最多3家企业)
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计/预测/年复合成长率(註:基于可行性检查)
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 介绍
  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 新兴市场
  • 新型冠状病毒感染疾病(COVID-19)的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球人类微生物组市场:副产品

  • 介绍
  • 医疗食品
  • 益生元
  • 益生菌
  • 共生学
  • 其他产品

第6章全球人类微生物组市场:依疾病分类

  • 介绍
  • 代谢
  • 内分泌
  • 传染性的

第7章全球人类微生物组市场:依类型

  • 介绍
  • 癌症
  • 代谢和胃肠道疾病
  • 自体免疫疾病
  • 肥胖
  • 其他类型

第8章全球人类微生物组市场:依应用分类

  • 介绍
  • 诊断
  • 治疗
  • 其他用途

第9章全球人类微生物组市场:按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 中东和非洲其他地区

第10章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第11章公司简介

  • Seres Therapeutics
  • Second Genome Inc.
  • Osel Inc.
  • Exeliom Biosciences SAS
  • Ginkgo Bioworks
  • Finch Therapeutics Group Inc.
  • Evelo Biosciences Inc
  • DuPont
  • Axial Biotherapeutics, Inc.
  • Astarte Medical
Product Code: SMRC24181

According to Stratistics MRC, the Global Human Microbiome Market is accounted for $0.8 billion in 2023 and is expected to reach $6.3 billion by 2030 growing at a CAGR of 34.1% during the forecast period. The term "Human Microbiomes Market" defines the area of biotechnology and healthcare that focuses on the thorough study, analysis, and commercial applications of the human microbiome, which is the enormous and diverse community of microorganisms that exists both inside and outside the human body. To comprehend the symbiotic interaction between the human body and its resident microorganisms, it comprises a variety of fields, including research, diagnostics, treatments, and customized medicine.

According to the American Cancer Society, 2022 estimates, there are about 1,918,030 new cases of cancer will be reported in the United States in 2022. Additionally, according to the Globocan 2020 statistics, there are 274,364 new cases of cancer and is expected to reach 400,564 new cases by 2040.

Market Dynamics:

Driver:

Research advances in the microbiome

An enormous shift has occurred in the comprehension of the human microbiome's involvement in human health and disease as a result of the substantial advancements made in the investigation of it over the past few decades. Additionally, the tremendous community of microorganisms that reside inside the human body has been thoroughly analyzed and characterized because of high-throughput sequencing methods and powerful bioinformatics tools.

Restraint:

Regulatory barriers

The lack of transparent and uniform regulatory processes for microbiome-based products and treatments is one of the main problems. The absence of simple and uniform regulatory frameworks for microbiome-based products and treatments may limit market expansion and increase entry hurdles. However, the variety of microbial communities and the dynamic nature of the human microbiome present difficulties for regulatory authorities when evaluating products' safety and efficacy.

Opportunity:

Chronic disease prevalence is on the rise

Globally, chronic illnesses such as obesity, diabetes, inflammatory bowel diseases, and autoimmune disorders are becoming more prevalent. As a result, in order to better understand and manage these chronic diseases, medical professionals and academics are exploring microbiome-based therapies. Additionally, the restoration of microbial equilibrium among individuals with chronic illnesses involves a number of developing methods, including probiotics, fecal microbiota transplantation (FMT), and microbiome regulation.

Threat:

Research and development expenses

In order to fully comprehend the complexity of the human microbiome as well as develop products and eliminates that are based on it, the field of microbiome research requires significant investments in research and development (R&D). The creation of microbiome therapies like probiotics and prebiotics, as well as data analysis, clinical trials, and microbiome sequencing, are all included in these expenditures. However, the variety of products and treatments available may be hampered by the high cost of R&D, which may prevent smaller businesses and startups from entering the market.

COVID-19 Impact:

Clinical trial research has been significantly hampered worldwide by the COVID-19 epidemic. Given that studies usually include poor people who are most in danger from COVID-19 exposure, this is very important. Similarly, COVID-19 has had a detrimental effect and might still have one on the operations of other companies, including their preclinical research and clinical testing of microbiome-based drugs and diagnostic instruments.

The probiotics segment is expected to be the largest during the forecast period

The segment for probiotics is anticipated to be the largest during the forecast period. Probiotics are living microorganisms that, when administered to a host in sufficient proportions, improve or maintain the host's overall health by restoring or maintaining their intestinal microbiome. Due to their significance in promoting immune health, boosting digestion, and potentially affecting a number of different elements of general wellbeing, they have grown tremendously popular. Furthermore, with an increasing emphasis on preventive health and wellness, the probiotics sector is anticipated to develop as customers look for microbiome-friendly remedies to their medical issues.

The diagnostics segment is expected to have the highest CAGR during the forecast period

Due to the growing awareness of the crucial role played by the human microbiome in health and illness, the diagnostics segment is anticipated to have the highest growth rate throughout the projection period. Microbiome diagnostics can offer a deeper comprehension of the microbial populations within the body due to developments in sequencing technologies and bioinformatics, enabling personalized and precise therapy. Moreover, microbiome diagnostics are also becoming more popular in healthcare due to their potential to support early disease detection, guide individualized treatment strategies, and assess the success of interventions.

Region with largest share:

North America held the largest share due to an established network of healthcare facilities, greater investment from major firms in developing more advanced technology, accelerating the process of creating new drugs, and a rise in research efforts in this field. Additionally, human microbiome treatments are getting more attention, lifestyle ailments are becoming more prevalent, and next-generation sequencing and the human microbiome are experiencing more technological advancements. These factors are all contributing to the market's growth in the region.

Region with highest CAGR:

Due to growing consumer interest in probiotics, prebiotics, and microbiome-focused products, the Asia-Pacific area is predicted to experience profitable growth. This is due to digestion, nutritional wellness, and the importance of the microbiome in overall well-being which are becoming more widely recognized. Additionally, the Asia Pacific area has experienced a rise in research and development activities in the field of microbiome science, especially in nations like China, Japan, and South Korea that have made significant investments in biotechnology and the life sciences.

Key players in the market

Some of the key players in Human Microbiome market include: Seres Therapeutics, Second Genome Inc., Osel Inc., Exeliom Biosciences SAS, Ginkgo Bioworks, Finch Therapeutics Group Inc., Evelo Biosciences Inc, DuPont, Axial Biotherapeutics, Inc. and Astarte Medical.

Key Developments:

In January 2023, Genetic Analysis AS, a research driven diagnostic company that focuses on innovative diagnostic solutions with microbiota analysis, entered into an agreement with Microbiome Research Pvt. Ltd., a India-based microbiome company, for launching a test service portfolio based on the GA-map Dysbiosis Test, and thus, making it the first CE-IVD marked standardized gut microbiome test.

In May 2022, 4D Pharma, a global pharmaceutical company that develops biotherapeutic products for diseases such as cancer, asthma, autism, and autoimmune conditions such as arthritis, announced clinical trial for MRx0518 with combination bavencio, a PD - L1 blocking antibody indicated for the treatment of urothelial cancer

Products Covered:

  • Medical Foods
  • Prebiotics
  • Probiotics
  • Symboitics
  • Other Products

Diseases Covered:

  • Metabolic
  • Endocrine
  • Infectious

Types Covered:

  • Cancer
  • Metabolic and Gastrointestinal Disorders
  • Autoimmune Disorder
  • Obesity
  • Other Types

Applications Covered:

  • Diagnostics
  • Therapeutics
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Human Microbiome Market, By Product

  • 5.1 Introduction
  • 5.2 Medical Foods
  • 5.3 Prebiotics
  • 5.4 Probiotics
  • 5.5 Symboitics
  • 5.6 Other Products

6 Global Human Microbiome Market, By Disease

  • 6.1 Introduction
  • 6.2 Metabolic
  • 6.3 Endocrine
  • 6.4 Infectious

7 Global Human Microbiome Market, By Type

  • 7.1 Introduction
  • 7.2 Cancer
  • 7.3 Metabolic and Gastrointestinal Disorders
  • 7.4 Autoimmune Disorder
  • 7.5 Obesity
  • 7.6 Other Types

8 Global Human Microbiome Market, By Application

  • 8.1 Introduction
  • 8.2 Diagnostics
  • 8.3 Therapeutics
  • 8.4 Other Applications

9 Global Human Microbiome Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Seres Therapeutics
  • 11.2 Second Genome Inc.
  • 11.3 Osel Inc.
  • 11.4 Exeliom Biosciences SAS
  • 11.5 Ginkgo Bioworks
  • 11.6 Finch Therapeutics Group Inc.
  • 11.7 Evelo Biosciences Inc
  • 11.8 DuPont
  • 11.9 Axial Biotherapeutics, Inc.
  • 11.10 Astarte Medical

List of Tables

  • Table 1 Global Human Microbiome Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Human Microbiome Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Human Microbiome Market Outlook, By Medical Foods (2021-2030) ($MN)
  • Table 4 Global Human Microbiome Market Outlook, By Prebiotics (2021-2030) ($MN)
  • Table 5 Global Human Microbiome Market Outlook, By Probiotics (2021-2030) ($MN)
  • Table 6 Global Human Microbiome Market Outlook, By Symboitics (2021-2030) ($MN)
  • Table 7 Global Human Microbiome Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 8 Global Human Microbiome Market Outlook, By Disease (2021-2030) ($MN)
  • Table 9 Global Human Microbiome Market Outlook, By Metabolic (2021-2030) ($MN)
  • Table 10 Global Human Microbiome Market Outlook, By Endocrine (2021-2030) ($MN)
  • Table 11 Global Human Microbiome Market Outlook, By Infectious (2021-2030) ($MN)
  • Table 12 Global Human Microbiome Market Outlook, By Type (2021-2030) ($MN)
  • Table 13 Global Human Microbiome Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 14 Global Human Microbiome Market Outlook, By Metabolic and Gastrointestinal Disorders (2021-2030) ($MN)
  • Table 15 Global Human Microbiome Market Outlook, By Autoimmune Disorder (2021-2030) ($MN)
  • Table 16 Global Human Microbiome Market Outlook, By Obesity (2021-2030) ($MN)
  • Table 17 Global Human Microbiome Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 18 Global Human Microbiome Market Outlook, By Application (2021-2030) ($MN)
  • Table 19 Global Human Microbiome Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 20 Global Human Microbiome Market Outlook, By Therapeutics (2021-2030) ($MN)
  • Table 21 Global Human Microbiome Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 22 North America Human Microbiome Market Outlook, By Country (2021-2030) ($MN)
  • Table 23 North America Human Microbiome Market Outlook, By Product (2021-2030) ($MN)
  • Table 24 North America Human Microbiome Market Outlook, By Medical Foods (2021-2030) ($MN)
  • Table 25 North America Human Microbiome Market Outlook, By Prebiotics (2021-2030) ($MN)
  • Table 26 North America Human Microbiome Market Outlook, By Probiotics (2021-2030) ($MN)
  • Table 27 North America Human Microbiome Market Outlook, By Symboitics (2021-2030) ($MN)
  • Table 28 North America Human Microbiome Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 29 North America Human Microbiome Market Outlook, By Disease (2021-2030) ($MN)
  • Table 30 North America Human Microbiome Market Outlook, By Metabolic (2021-2030) ($MN)
  • Table 31 North America Human Microbiome Market Outlook, By Endocrine (2021-2030) ($MN)
  • Table 32 North America Human Microbiome Market Outlook, By Infectious (2021-2030) ($MN)
  • Table 33 North America Human Microbiome Market Outlook, By Type (2021-2030) ($MN)
  • Table 34 North America Human Microbiome Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 35 North America Human Microbiome Market Outlook, By Metabolic and Gastrointestinal Disorders (2021-2030) ($MN)
  • Table 36 North America Human Microbiome Market Outlook, By Autoimmune Disorder (2021-2030) ($MN)
  • Table 37 North America Human Microbiome Market Outlook, By Obesity (2021-2030) ($MN)
  • Table 38 North America Human Microbiome Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 39 North America Human Microbiome Market Outlook, By Application (2021-2030) ($MN)
  • Table 40 North America Human Microbiome Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 41 North America Human Microbiome Market Outlook, By Therapeutics (2021-2030) ($MN)
  • Table 42 North America Human Microbiome Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 43 Europe Human Microbiome Market Outlook, By Country (2021-2030) ($MN)
  • Table 44 Europe Human Microbiome Market Outlook, By Product (2021-2030) ($MN)
  • Table 45 Europe Human Microbiome Market Outlook, By Medical Foods (2021-2030) ($MN)
  • Table 46 Europe Human Microbiome Market Outlook, By Prebiotics (2021-2030) ($MN)
  • Table 47 Europe Human Microbiome Market Outlook, By Probiotics (2021-2030) ($MN)
  • Table 48 Europe Human Microbiome Market Outlook, By Symboitics (2021-2030) ($MN)
  • Table 49 Europe Human Microbiome Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 50 Europe Human Microbiome Market Outlook, By Disease (2021-2030) ($MN)
  • Table 51 Europe Human Microbiome Market Outlook, By Metabolic (2021-2030) ($MN)
  • Table 52 Europe Human Microbiome Market Outlook, By Endocrine (2021-2030) ($MN)
  • Table 53 Europe Human Microbiome Market Outlook, By Infectious (2021-2030) ($MN)
  • Table 54 Europe Human Microbiome Market Outlook, By Type (2021-2030) ($MN)
  • Table 55 Europe Human Microbiome Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 56 Europe Human Microbiome Market Outlook, By Metabolic and Gastrointestinal Disorders (2021-2030) ($MN)
  • Table 57 Europe Human Microbiome Market Outlook, By Autoimmune Disorder (2021-2030) ($MN)
  • Table 58 Europe Human Microbiome Market Outlook, By Obesity (2021-2030) ($MN)
  • Table 59 Europe Human Microbiome Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 60 Europe Human Microbiome Market Outlook, By Application (2021-2030) ($MN)
  • Table 61 Europe Human Microbiome Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 62 Europe Human Microbiome Market Outlook, By Therapeutics (2021-2030) ($MN)
  • Table 63 Europe Human Microbiome Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 64 Asia Pacific Human Microbiome Market Outlook, By Country (2021-2030) ($MN)
  • Table 65 Asia Pacific Human Microbiome Market Outlook, By Product (2021-2030) ($MN)
  • Table 66 Asia Pacific Human Microbiome Market Outlook, By Medical Foods (2021-2030) ($MN)
  • Table 67 Asia Pacific Human Microbiome Market Outlook, By Prebiotics (2021-2030) ($MN)
  • Table 68 Asia Pacific Human Microbiome Market Outlook, By Probiotics (2021-2030) ($MN)
  • Table 69 Asia Pacific Human Microbiome Market Outlook, By Symboitics (2021-2030) ($MN)
  • Table 70 Asia Pacific Human Microbiome Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 71 Asia Pacific Human Microbiome Market Outlook, By Disease (2021-2030) ($MN)
  • Table 72 Asia Pacific Human Microbiome Market Outlook, By Metabolic (2021-2030) ($MN)
  • Table 73 Asia Pacific Human Microbiome Market Outlook, By Endocrine (2021-2030) ($MN)
  • Table 74 Asia Pacific Human Microbiome Market Outlook, By Infectious (2021-2030) ($MN)
  • Table 75 Asia Pacific Human Microbiome Market Outlook, By Type (2021-2030) ($MN)
  • Table 76 Asia Pacific Human Microbiome Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 77 Asia Pacific Human Microbiome Market Outlook, By Metabolic and Gastrointestinal Disorders (2021-2030) ($MN)
  • Table 78 Asia Pacific Human Microbiome Market Outlook, By Autoimmune Disorder (2021-2030) ($MN)
  • Table 79 Asia Pacific Human Microbiome Market Outlook, By Obesity (2021-2030) ($MN)
  • Table 80 Asia Pacific Human Microbiome Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 81 Asia Pacific Human Microbiome Market Outlook, By Application (2021-2030) ($MN)
  • Table 82 Asia Pacific Human Microbiome Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 83 Asia Pacific Human Microbiome Market Outlook, By Therapeutics (2021-2030) ($MN)
  • Table 84 Asia Pacific Human Microbiome Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 85 South America Human Microbiome Market Outlook, By Country (2021-2030) ($MN)
  • Table 86 South America Human Microbiome Market Outlook, By Product (2021-2030) ($MN)
  • Table 87 South America Human Microbiome Market Outlook, By Medical Foods (2021-2030) ($MN)
  • Table 88 South America Human Microbiome Market Outlook, By Prebiotics (2021-2030) ($MN)
  • Table 89 South America Human Microbiome Market Outlook, By Probiotics (2021-2030) ($MN)
  • Table 90 South America Human Microbiome Market Outlook, By Symboitics (2021-2030) ($MN)
  • Table 91 South America Human Microbiome Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 92 South America Human Microbiome Market Outlook, By Disease (2021-2030) ($MN)
  • Table 93 South America Human Microbiome Market Outlook, By Metabolic (2021-2030) ($MN)
  • Table 94 South America Human Microbiome Market Outlook, By Endocrine (2021-2030) ($MN)
  • Table 95 South America Human Microbiome Market Outlook, By Infectious (2021-2030) ($MN)
  • Table 96 South America Human Microbiome Market Outlook, By Type (2021-2030) ($MN)
  • Table 97 South America Human Microbiome Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 98 South America Human Microbiome Market Outlook, By Metabolic and Gastrointestinal Disorders (2021-2030) ($MN)
  • Table 99 South America Human Microbiome Market Outlook, By Autoimmune Disorder (2021-2030) ($MN)
  • Table 100 South America Human Microbiome Market Outlook, By Obesity (2021-2030) ($MN)
  • Table 101 South America Human Microbiome Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 102 South America Human Microbiome Market Outlook, By Application (2021-2030) ($MN)
  • Table 103 South America Human Microbiome Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 104 South America Human Microbiome Market Outlook, By Therapeutics (2021-2030) ($MN)
  • Table 105 South America Human Microbiome Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 106 Middle East & Africa Human Microbiome Market Outlook, By Country (2021-2030) ($MN)
  • Table 107 Middle East & Africa Human Microbiome Market Outlook, By Product (2021-2030) ($MN)
  • Table 108 Middle East & Africa Human Microbiome Market Outlook, By Medical Foods (2021-2030) ($MN)
  • Table 109 Middle East & Africa Human Microbiome Market Outlook, By Prebiotics (2021-2030) ($MN)
  • Table 110 Middle East & Africa Human Microbiome Market Outlook, By Probiotics (2021-2030) ($MN)
  • Table 111 Middle East & Africa Human Microbiome Market Outlook, By Symboitics (2021-2030) ($MN)
  • Table 112 Middle East & Africa Human Microbiome Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 113 Middle East & Africa Human Microbiome Market Outlook, By Disease (2021-2030) ($MN)
  • Table 114 Middle East & Africa Human Microbiome Market Outlook, By Metabolic (2021-2030) ($MN)
  • Table 115 Middle East & Africa Human Microbiome Market Outlook, By Endocrine (2021-2030) ($MN)
  • Table 116 Middle East & Africa Human Microbiome Market Outlook, By Infectious (2021-2030) ($MN)
  • Table 117 Middle East & Africa Human Microbiome Market Outlook, By Type (2021-2030) ($MN)
  • Table 118 Middle East & Africa Human Microbiome Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 119 Middle East & Africa Human Microbiome Market Outlook, By Metabolic and Gastrointestinal Disorders (2021-2030) ($MN)
  • Table 120 Middle East & Africa Human Microbiome Market Outlook, By Autoimmune Disorder (2021-2030) ($MN)
  • Table 121 Middle East & Africa Human Microbiome Market Outlook, By Obesity (2021-2030) ($MN)
  • Table 122 Middle East & Africa Human Microbiome Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 123 Middle East & Africa Human Microbiome Market Outlook, By Application (2021-2030) ($MN)
  • Table 124 Middle East & Africa Human Microbiome Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 125 Middle East & Africa Human Microbiome Market Outlook, By Therapeutics (2021-2030) ($MN)
  • Table 126 Middle East & Africa Human Microbiome Market Outlook, By Other Applications (2021-2030) ($MN)